BRD2 and prostate cancer: In the same line, a study proposed that exogenous FSH administration could increase xenograft tumors of androgen-independent human PC-3 PCa cells [in castrated mice with endogenous FSH suppression (degarelix-treated, a GnRH antagonist) or in castrated mice], and in androgen-independent human prostate cancer cells DU-145 (in degarelix treated mice) [83].